SHANGHAI, China & CUPERTINO, Calif.—Cellular Biomedicine Group Inc. (CBMG) has completed its newly expanded 30,000-square-foot facility in Huishan High Tech Park in Wuxi, China. An expected 20,000 square feet of the Wuxi GMP facility will be used for advanced stem cell culturing, centralized plasmid and viral vector production, cell banking and reagent development. The company believes that this facility, together with its Zhangjiang Shanghai and Beijing GMP facilities, will be able to support simultaneous clinical trials for five different CAR-T and stem cell products, or have the capacity to treat up to 10,000 cancer and 10,000 knee osteoarthritis patients annually.